DYLAN BOYD: Open Payments
NPI 1891357588 · HATTIESBURG, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,054 in 212 payments from 28 companies in 2025. Trend: 2023 $3,507 · 2024 $3,584 · 2025 $4,054
Food & beverage: $4,011Education: $43
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 36 | $853 |
| Viatris Specialty LLC | 32 | $454 |
| GlaxoSmithKline, LLC. | 28 | $390 |
| Grifols USA, LLC | 13 | $314 |
| GENZYME CORPORATION | 11 | $270 |
| JAZZ PHARMACEUTICALS INC. | 10 | $228 |
| Verona Pharma, Inc. | 13 | $221 |
| Regeneron Healthcare Solutions, Inc. | 9 | $219 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 12 | $208 |
| ANI Pharmaceuticals, Inc. | 6 | $140 |
Products named: DUPIXENT, YUPELRI, TEZSPIRE, Prolastin-C Liquid, TRELEGY ELLIPTA, XYWAV, Ohtuvayre, FASENRA.
Industry payments across MS — which companies pay providers there.
